

# PRIME / QIP

## QIP PY<sub>4-8</sub> Survey Prelim Results

---

Wednesday, July 22, 2020, 12-1:30PM

[Play recording](#)

Presenters: David Lown [dlownd@caph.org](mailto:dlownd@caph.org), Dana Pong [dpong@caph.org](mailto:dpong@caph.org)  
Recordings of the webinar and slide deck posted on [SNI Link/QIP/Webinars](#)

# Housekeeping

---



**Lines are muted on entry.**

Please don't use a speakerphone in order to prevent an audio feedback loop, an echo.



At any time, feel free to chat your question & we will read out. Please raise your hand if you have a verbal question and we will unmute you.



Webinar will be recorded and saved on SNI Link: [PRIME Webinars](#) and [QIP Webinars](#)

# Updates

---

# Early PY3 Reporting/Payment

	2020						2021								
Task	Jul	Aug	Sept	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept
<b>QIP Portal</b>															
Update Portal with changes for reporting PY3 Feb performance against 25th percentile															
Portal Testing															
Portal Open for data entry			Sept 1-9												
<b>Expedited PY3 reporting &amp; Payment</b>															
Due date for MCP data to DPHs			Paid in FY20/21	Paid in FY21/22											
Submission of DPH reports to OMD															
OMD Review*															
CRDD adjust MCP rates --> DPH IGTs to DHCS															
DHCS payments to MCP															
MCP Payments to DPH															
<b>QIP PY4 Manual Tasks</b>															
OMD Finalize Metric Set															
Manual Review															

\*dependent on submission of complete DPH reports & rapid DPH responses to DHCS ?s & no PRIME Extensions  
 October blocked for PRIME Data Completeness Review

# QIP PY<sub>4</sub>-8 Prelim Survey Results

---

# PY4: Updates

---

- New “Modified Exclusive Breast Milk Feeding”.
  - Added exclusions for “Strict Contradindications to Breast Milk Feeding”
  - Would be used in QIP if voted in, so use when considering your vote on EBF

## **Strict Contraindications to Breast Milk Feeding:**

- **Maternal:** HIV, open HSV lesions, cracked/bleeding nipples with Hepatitis C, human T-cell lymphotropic virus I or II, untreated brucellosis, breast tissue removal, illicit drug use, cytotoxic chemotherapy, pharmacologic contraindications
- **Newborn:** galactosemia, maple syrup urine disease, phenylketonuria (PKU), comfort care/hospice

*It's important to note that there are several scenarios where it is important to supplement the infant: maternal delayed lactogenesis, neonatal hypoglycemia, low birth weight, infants of diabetic mothers, etc. These are theoretically all cases where the infant could be safely supplemented with expressed maternal breast milk or donor milk in lieu of formula and are therefore **NOT** strict contraindications.*

# PY4: Updates

- Audiological Diagnosis Target Pop
  - Changed from “MCMC Assigned Lives” to “Payer Agnostic”
- Live Births Weighing <2500 gms:
  - 12 “No”, **3 Yes, 1 “Yes but...”** → Just say “No”
- HEDIS First Year Measures would start PY5. Use Retired measures in PY4:
  - Child and Adolescent Well-Care Visits (WCV), merge of:
    - Retired: Adolescent Well Visits (AWV)
    - Retired: Well Child Visits 3-6 (W34)
  - Kidney Health Evaluation for Patients With Diabetes
    - Retired: Comprehensive Diabetes Care: Medical Attention for Nephropathy

Metric Name	Yes	Yes but	No	TBD
Childhood and Adolescent Well Care Visits	7	4	5	1
Kidney Health Evaluation for Patients With Diabetes	7	6	3	1

# PY4: “Improve Equity” metric to be proposed

---

Description: Demonstrate performance improvement for a selected metric and priority population/s

- Metric Options:
  - Any metric from PY4-8 metric set that is also in MCAS and has an MPL
  - Colorectal Cancer Screening
- Baseline: Prior calendar year performance
- Target Setting: 10% gap closure to state/national benchmark
- Proviso: If priority group achieves  $\geq 90^{\text{th}}$  %ile in any single PY  $\rightarrow$  3 PYs later must choose new metric and/or group from QIP menu
  - No “backsies” rule: Even if the performance on the priority group drops below  $90^{\text{th}}$  in subsequent years (regardless of whether you report on it or not), by the 3<sup>rd</sup> PY after achieving  $90^{\text{th}}$  percentile performance, if the system wants to continue to report on the metric, they are required to report on a different metric/priority population



# PY4: 6/16/2020 Survey Version

---

Make sure you are using the Survey from 6/16/2020 and not from 3/9/2020. The 6/16/2020 survey does not include:

- Adolescent Well-Care Visits
- Adult Body Mass Index Assessment
- Comprehensive Diabetes Care: Medical Attention for Nephropathy
- Comprehensive Diabetes Care: Foot Exam
- Disease Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis
- Medication Management for People with Asthma
- Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life

# Summary of Prelim Votes

---

- Only “Yes”: 9
- Majority “Yes”: 60
- Tie: 1
- Majority “No”: 12
- Only “No”: 1

# Majority “No” (13)

Metric Name	Bench mark	No	Yes, but	Yes
Annual Dental Visit (2-20)	HEDIS	15	0	0
Audiological Diagnosis No Later Than 3 Months of Age	CDC	11	4	1
Contraceptive Care – Postpartum Women Ages 15–44	DHCS	10	3	0
Follow-Up Care for Children Prescribed ADHD Meds	HEDIS	12	3	0
HIV Linkage to Care	FQHC	10	4	2
Live Births Weighing Less Than 2,500 Grams <b>JUST SAY NO!</b>	FQHC	12	1	3
% Eligibles Who Received Preventive Dental Services	CMS Core	14	1	0
Primary Caries Prevention Intervention	DHCS?	12	3	0
Proportion Admitted to Hospice for Less than 3 Days	QPP v DHCS	14	2	1
Use of Opioids From Multiple Providers (Multiple Pharmacies)	HEDIS	10	4	3
Use of Spirometry Testing in the Assessment and Diagnosis of COPD	HEDIS	9	5	2
Follow-Up After ED Visit for Alcohol and Other Drug Abuse or Dependence	HEDIS	8	6	0
Contraceptive Care – All Women Ages 15–44	DHCS	8	4	3

# Majority “No” (13)

Metric Name	Bench mark	No	Yes, but	Yes
Annual Dental Visit (2-20)	HEDIS	15	0	0
Proportion Admitted to Hospice for Less than 3 Days	QPP v DHCS	14	2	1
% Eligibles Who Received Preventive Dental Services	CMS Core	14	1	0
Follow-Up Care for Children Prescribed ADHD Meds	HEDIS	12	3	0
Primary Caries Prevention Intervention	DHCS?	12	3	0
Live Births Weighing Less Than 2,500 Grams <b>JUST SAY NO!</b>	FQHC	12	1	3
Audiological Diagnosis No Later Than 3 Months of Age	CDC	11	4	1
Use of Opioids From Multiple Providers (Multiple Pharmacies)	HEDIS	10	4	3
HIV Linkage to Care	FQHC	10	4	2
Contraceptive Care – Postpartum Women Ages 15–44	DHCS	10	3	0
Use of Spirometry Testing in the Assessment and Diagnosis of COPD	HEDIS	9	5	2
Follow-Up After ED Visit for Alcohol and Other Drug Abuse or Dependence	HEDIS	8	6	0
Contraceptive Care – All Women Ages 15–44	DHCS	8	4	3

# Only Yes (9)

Metric Name	Benchmark category	Yes	Yes, but
Colorectal Cancer Screening	FQHC	14	3
Diabetes: Blood Pressure Control	HEDIS	14	3
Diabetes: HbA1c Poor Control (>9.0%)	HEDIS	15	2
Controlling High Blood Pressure	HEDIS	14	3
Prevention of CVC - Related Bloodstream Infections	QPP	12	5
Preventive Care and Screening: Influenza Immunization	QPP vs DHCS?	13	4
Reconciled Med List Received by Discharged Patients	Entities? PRIME(32)	15	2
Screening for Depression and Follow-Up Plan	FQHC, CA	12	5
Tobacco Assessment and Counseling	FQHC, CA	15	2

# Majority Yes (63) & Medicaid Applicable Benchmarks

---

- 26: No
  - 2 HEDIS: WCV & KED
  - 9 QPP
    - 3 Admin only: **Theoretically could** be DHCS calculated
    - 6 EHR data: Not calculable by DHCS
  - 15 Non-QPP
    - 3 Admin only: **Theoretically could** be DHCS calculated
    - 12 EHR data: Not calculable by DHCS
- 34: Yes

# QPP metrics (9)

Metric	Yes	Yes, but	No	Data for Benchmark
CAD: ACE/ARB Therapy - Diabetes or LVSD	14	2	1	DHCS?
CAD: Antiplatelet Therapy	14	2	1	DHCS?
CAD: Beta-Blocker Therapy-Prior MI or LVSD	14	2	1	DHCS?
Heart Failure: ACE/ARB/ARNI Therapy for LVSD	15	1	1	Entity?
Heart Failure: Beta-Blocker Therapy for LVSD	14	2	1	Entity?
Atrial Fibrillation/Flutter: Chronic Anticoag Tx	11	5	1	Entity?
Cardiac Stress Imaging (Low Risk Surgery Pts)	10	4	3	Entity?
ED Utilization of CT for Minor Blunt Head Trauma $\geq 18$ yo	5	4	7	Entity?
Screening for High BP & F/U Documented	4	6	5	Entity? PRIME (15)

# Spec use only admin data (3)

Metric	Yes	Yes, but	No	Data for Benchmark
Med reconciliation post discharge (MRP)*	14	2	1	HEDIS Medicare. DHCS data?
BIRADS to Biopsy	6	7	3	DHCS vs Entity? PRIME (11)
Unhealthy Alcohol Use Screening and Follow-Up**	6	5	4	DHCS vs Entity?

\*CAC recommended DHCS data over Medicare.

\*\*HEDIS First Year ECDS metric. No benchmark anticipated for 2021



# Specs include EHR data: Benchmark from Entity data? (1-6/12)

Metric Name	Yes	Yes, but	No	Benchmark data
Discharged on Antithrombotic Therapy (STK-2)	10	2	4	Entities?
Depression Remission or Response for Adolescents and Adults - Follow Up*	8	5	4	PRIME(23)
Specialty Care Touches: requests managed solely via non-in-person specialty encounters	8	3	6	PRIME(19)
Receipt of Appropriate Follow-up for Abnormal CRC Screening	8	3	5	PRIME(11)
Assessment and Management of Chronic Pain (Utox & Pain Agreement)	7	5	5	PRIME(15)
Request for Specialty Care Expertise Turnaround Time	7	4	6	PRIME(19)

\*HEDIS First Year ECDS metric. No benchmark anticipated for 2020

# Specs include EHR data: Benchmark from Entity data? (7-12/12)

---

Metric Name	Yes	Yes, but	No	Benchmark data
NHSN Antimicrobial Use Measure (AU)	7	3	6	PRIME(13)
Advance Care Plan*	6	6	4	PRIME (12)
Peri-operative Prophylactic Antibiotics Administered after Surgical Closure	6	6	4	PRIME(13)
Treatment Preferences (Inpatient)	6	4	5	PRIME(12)
HIV Screening Measure	5	5	5	Entities?
MWM#8 - Treatment Preferences (Outpatient)	5	4	6	PRIME(12)

\*Admin only spec but uses CPTII codes, minimal presence in DHCS data

# Majority Yes with Medicaid Benchmarks (1-12/34)

Metric Name	Bench mark	Yes, Yes but	No
Perioperative Care: VTE Prophylaxis	QPP	14 2	1
Breast Cancer Screening	HEDIS	13 3	1
Cervical Cancer Screening	HEDIS	13 3	1
Diabetes: Hemoglobin A1c (HbA1c) Control (<8%)	HEDIS	13 3	1
Immunizations for Adolescents	HEDIS	12 3	2
Childhood Immunization Status (CIS 10)	HEDIS	12 2	2
HIV Viral Load Suppression	DHCS	11 4	2
Prenatal and Postpartum Care	HEDIS	10 5	1
Appropriate Treatment for Upper Respiratory Infection	HEDIS	10 4	1
Exclusive Breast Milk Feeding (PC-05)	CMQCC	10 3	4
Concurrent Use of Opioids and Benzodiazepines	DHCS	10 2	5
Comprehensive Diabetes Control: Eye Exam	HEDIS	9 6	2

# Majority Yes with Medicaid Benchmarks (13-23/34)

Metric Name	Bench mark	Yes, Yesbut	No
Lead Screening in Children	HEDIS	9 5	2
Chlamydia Screening in Women (16–24yo Total)	HEDIS	9 5	1
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis	HEDIS	8 4	4
Well-Child Visits in the First 15 Months of Life	HEDIS	8 3	6
Plan All-Cause Readmissions	DHCS	7 8	2
Use of Opioids at High Dosage in Persons Without Cancer	DHCS	7 5	5
PC-01: Elective Delivery*	CMQCC	7 5	3
BMI Screening and Follow-up	FQHC	7 4	4
Surgical Site Infection (SSI)	CDPH	7 3	7
PC-02: Cesarean Birth	CMQCC	6 6	5
Persistence of Beta-Blocker Treatment after a Heart Attack	HEDIS	6 5	6

# Majority Yes with Medicaid Benchmarks (24-34)

Metric Name	Bench mark	Yes, Yesbut	No
Asthma Medication Ratio: Ages 5–64	HEDIS	6 5	5
Statin Therapy for Patients With Diabetes	HEDIS	6 4	7
Reduction in Hospital Acquired C Difficile Infections	NHSN CA	6 4	6
Appropriate Testing for Pharyngitis	HEDIS	6 4	5
Weight Assessment & Counseling for Nutrition and Physical Activity for Children & Adolescents	HEDIS	5 7	5
Statin Therapy For The Prevention And Treatment Of Cardiovascular Disease	FQHC	5 6	6
Statin Therapy for Patients With Cardiovascular Disease	HEDIS	5 6	6
Non-Recommended Cervical Cancer Screening in Adolescent Females	HEDIS	5 5	5
Use of Imaging Studies for Low Back Pain	HEDIS	5 4	7
Developmental Screening in the First Three Years of Life	CMS - states	4 5	7
Pharmacotherapy Management of COPD Exacerbation	HEDIS	2 8	4

# Q&A: QIP

---

- Q